NCT06382987Recruiting
A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)
Registry of Psoriasis Health Outcomes: A Longitudinal Real-world Collaboration (RePhlect) - A Real-World, Prospective, Observational Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan
Source: ClinicalTrials.gov · Last updated 25 Apr 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a prospective, observational, real-world study of adult participants in Japan with physician-reported diagnosis of plaque psoriasis treated with deucravacitinib or apremilast.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 600 (estimated)
- First submitted
- 22 Apr 2024
- Start date
- 22 Jan 2024
- Primary completion date
- 31 Dec 2029
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Psoriasis
- NCT number
- NCT06382987
What you commit to
- Study type: Observational
- Planned participants: 600
- From 22 Jan 2024 to the primary completion date, 31 Dec 2029
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous treatment experience with the treatment of interest (e.g. patients who have history of apremilast will not be eligible to be enrolled in apremilast arm of the study and similar for deucravacitinib)
Other
- Participants currently participating in or planning to participate in an interventional clinical trial
- Patients enrolled in deucravacitinib post-marketing surveillance study (ClinicalTrial.gov ID: NCT05633264)
Who the study is looking for
- Japanese adult participants aged 18 years old or older
- Physician-reported diagnosis of plaque psoriasis
- Newly initiating deucravacitinib or apremilast according to the label
- Participants who have signed informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fukuoka University Hospital Coordinator of this site? Confirm its status | Fukuoka | Japan | Recruiting |
| Mebix. Inc Coordinator of this site? Confirm its status | Minato-ku | Japan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.